UNITED STATES
SECURITIES EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2006.
PHARMAFRONTIERS CORP.
(Exact name of registrant as specified in its charter)
Texas 000-25513 76-0333165
- ----------------------- ----------------------- ------------------------
(State of organization) (Commission File Number) (IRS Employer
2635 N. Crescent Ridge Drive
The Woodlands, Texas 77381
- ------------------------------------------------ -----------------
(Address of principal executive offices) (Zip Code)
Registrant's Telephone Number, including area code: (281) 272-9331
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a- 12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On January 13, 2006, Registrant entered into a License Agreement (the
"License Agreement") with the Shanghai Institute for Biological Science, China
Academy of Science of the People's Republic of China. The License Agreement
grants Registrant an exclusive worldwide license to certain technology relating
to a T cell vaccine for rheumatoid arthritis developed by the Shanghai Institute
for Biological Science. The Registrant will request confidential treatment from
the Commission for certain terms in the License Agreement in connection with the
filing of the License Agreement as an exhibit to its Annual Report on Form 10-K
for the year ended December 31, 2005.
On January 17, 2006 Registrant issued a press release reporting the
signing of the Amended License Agreement. A copy of the press release is
attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(c) Exhibit 99.1
The following exhibits are to be filed as part of this 8-K:
Exhibit No. Description
- ----------- -------------------------------------
99.1 Press release issued January 17, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMAFRONTIERS CORP.
By: /s/ David B. McWilliams
--------------------------------------------
David B. McWilliams, Chief Executive Officer
Date: January 17, 2006
EXHIBIT INDEX
Exhibit No. Description
99.1 Press release issued January 17, 2006.